TL;DR
The FDA has alerted health care providers that certain medical devices made in Japan by Olympus Medical Systems Corporation and its subsidiaries are subject to Import Alert 89-04. The alert blocks future shipments of listed models from entering the United States because of outstanding quality-system violations; it does not automatically require users to stop using devices already in service.
The U.S. Food and Drug Administration has alerted health care providers that specified medical devices manufactured in Japan by Olympus Medical Systems Corporation and its subsidiaries are covered by an import alert that bars future shipments from entering the United States. The FDA says the action reflects its continuing concerns about outstanding quality-system regulation violations; it says devices already in use may continue to be used if they are not experiencing problems.
The alert, described in an FDA letter dated October 20, 2026, is identified as Import Alert 89-04 and concerns failure to meet quality-system regulation requirements. The affected product categories include specified ureterorenoscopes, bronchoscopes, laparoscopes, automated endoscope reprocessors, ingestible telemetric gastrointestinal capsule imaging systems and enteroscopes. These devices are used for procedures and visualization in the urinary tract, respiratory tract, abdomen and pelvis, and small intestine, as well as for reprocessing endoscopes.
The FDA directs providers to check the listed model numbers and Unique Device Identifiers (UDIs) rather than assume every Olympus product is covered. The letter’s table includes numerous scope and reprocessor models, with a heading indicating the listed devices are effective from June 24, 2025. The source material provided for this report contains only part of the table, so providers should consult the FDA’s full list and the AccessGUDID database to verify a particular device.
The import alert applies to the specified devices, not related products such as replacement parts, connectors or single-use consumables. The FDA advises users to follow labeling and reprocessing instructions, avoid using damaged equipment or devices that fail a leak test, and arrange routine inspections and maintenance according to manufacturer instructions. If a listed device has been recalled, providers should follow the company’s recall notification for product-specific directions.
Effects on Device Supply and Care
The alert has two distinct implications: it restricts future imports of listed models and gives providers instructions for managing equipment already in clinical use. It does not, on the information in the letter, amount to a blanket direction to remove every affected device from service. The FDA says users may continue using devices already in use if they are not experiencing problems, while advising them to follow inspection, maintenance and reprocessing guidance.
That distinction matters to hospitals and clinics planning procedures and equipment availability. A shipment refusal can affect access to particular models, but the letter does not say that all Olympus devices, all products made in Japan or all related supplies are covered. Nor does the FDA recommend canceling or delaying procedures automatically. It advises clinicians to discuss the benefits and risks of procedures involving these devices with patients before making decisions.
The FDA also asks providers to report adverse events promptly. Such reports can help the agency identify and better understand device risks, while the import action addresses the agency’s stated compliance concerns. The letter does not describe a new finding that every listed device is defective or unsafe; it focuses on unresolved regulatory violations and provides handling guidance for devices in use.
As an affiliate, we earn on qualifying purchases.
Earlier FDA Compliance Actions
The letter places the import alert within a longer series of FDA actions concerning Olympus. The agency says it has previously issued warning letters and import alerts related to current good manufacturing practice requirements and reporting requirements, including requirements involving recalls. It describes recalls identified by the FDA as the most serious type of recall, but the letter does not establish that every model in this alert has been recalled.
The FDA says it has made extensive and ongoing efforts to address compliance issues and continues to monitor corrective actions tied to device quality violations. It says the import alert is intended to prevent future shipments of the specified devices from entering the United States. The letter does not provide a full account of the underlying violations, the corrective actions Olympus has taken, or the agency’s detailed assessment of those actions.
The device table uses Unique Device Identifiers to help distinguish products. The FDA established the UDI system to identify medical devices sold in the United States from manufacturing through distribution and use. Providers can use the model and device identifier information in the alert to check whether a specific unit falls within the listed scope.
““Despite extensive and ongoing efforts to address compliance issues, the FDA continues to have concerns related to outstanding Quality System regulation violations by Olympus.””
— U.S. Food and Drug Administration
As an affiliate, we earn on qualifying purchases.
Scope and Corrective Actions
The letter does not detail the specific quality-system violations still outstanding, explain which corrective actions remain incomplete, or state when the import restriction might be changed. It also does not quantify the number of devices or shipments affected, describe current inventory levels, or estimate the effect on care availability.
The supplied device table is incomplete, and the letter notes that some devices under the alert may have been recalled without identifying every recalled model in the information provided here. Whether a particular unit is included should be checked against the complete FDA list, its model number and UDI, as well as any manufacturer recall notice. The agency’s guidance that devices in use may continue to be used is conditional: it applies if they are not experiencing problems and does not replace recall instructions or routine safety checks.
gastrointestinal capsule imaging system
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Provider Checks and FDA Monitoring
Health care providers should compare devices in their facilities with the FDA’s complete Import Alert 89-04 list, using the model and UDI information, and check whether a manufacturer recall notice applies. For equipment that remains in use, the FDA advises following labeling and reprocessing instructions, inspecting and maintaining devices on schedule, and not using equipment that is damaged or fails a leak test.
Providers should discuss procedure-specific benefits and risks with patients rather than canceling or delaying procedures solely because of the alert. The FDA asks clinicians to report adverse events promptly and says it will continue monitoring Olympus’s corrective actions. The agency has not announced a date for lifting or revising the alert; further information will depend on regulatory developments and any new FDA updates.
As an affiliate, we earn on qualifying purchases.
Key Questions
Which Olympus products are covered by the import alert?
The alert covers specified models of devices made in Japan, including certain ureterorenoscopes, bronchoscopes, laparoscopes, endoscope reprocessors, capsule imaging systems and enteroscopes. Check the FDA’s full model and UDI list; it does not apply to every Olympus product.
Do providers have to stop using affected devices already in service?
Not automatically. The FDA says devices already in use may continue to be used if they are not experiencing problems. Providers should follow any applicable recall notice and the device’s labeling, reprocessing, inspection and maintenance instructions.
Does the alert cover replacement parts and consumables?
The letter says the alert does not apply to related products such as replacement parts, connectors or single-use consumables used with devices covered by the alert.
Does the FDA recommend canceling procedures involving these devices?
No automatic cancellation is recommended in the letter. The FDA advises providers to discuss the benefits and risks with patients before deciding whether a procedure should proceed, be delayed or be canceled.
Why did the FDA issue the import alert?
The FDA says it continues to have concerns about outstanding quality-system regulation violations by Olympus, despite ongoing efforts to address compliance issues. The alert is intended to prevent future shipments of the specified devices from entering the United States.
Source: primary
